Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors
The Pomerantz Law Firm has announced a thorough investigation into the claims made by investors of ImmunityBio, Inc. (NASDAQ: IBRX). This move has been prompted by accusations that the company and some of its executives may have engaged in potentially fraudulent activities or other unlawful business practices. Investors affected by these circumstances are encouraged to reach out to Danielle Peyton from Pomerantz for more information on how to participate in any potential legal proceedings.
Recently, ImmunityBio reported the findings from its Phase 2 clinical trial for a novel immunotherapy regimen targeting patients suffering from recurrent or progressive glioblastoma, a form of brain cancer. The results highlighted that the primary endpoint concerning median overall survival was pending, which raised significant concerns amongst eager investors. On January 23, 2026, the market reacted to this ambiguous update, resulting in a substantial drop of 12.13% in ImmunityBio's stock price, closing at $6.45 per share.
Compounding these woes, further complications arose on March 24, 2026 when a letter from the U.S. Food and Drug Administration (FDA) became public. The FDA reprimanded ImmunityBio for their continued promotion of Anktiva, a drug used in bladder cancer treatment, accusing the company of using misleading marketing strategies despite prior warnings. This revelation added to investor concerns; the stock plummeted another 21.12%, closing at $7.41 per share.
Pomerantz LLP, renowned for its expertise in corporate and securities class action litigation, has a history spanning over 85 years, championing the rights of investors. Founded by the influential Abraham L. Pomerantz, the firm has strategically tackled various cases of securities fraud, corporate misconduct, and breaches of fiduciary duty. Their record of securing significant damages for victims further emphasizes the commitment to justice and accountability in the corporate realm.
In this latest investigation, the firm aims to determine whether ImmunityBio misled its investors, potentially exposing them to significant financial loss. Through prompt action, the firm seeks to recover losses for affected shareholders and to hold accountable those responsible for any fraudulent practices. Investors who believe they may have suffered losses as a result of these events are warmly invited to connect with the Pomerantz team to discuss their situation and explore available options.
Potential investors and stakeholders are advised to stay updated on the developments surrounding ImmunityBio and the investigation led by Pomerantz Law Firm. Further clarity on the company's operations and communications with investors will likely evolve, potentially influencing market perceptions and stock performance in the coming months. If you wish to engage with the current legal discourse or need expert guidance regarding your legal rights as an investor in ImmunityBio, do not hesitate to contact Pomerantz at [email protected] or call 646-581-9980, extension 7980. Ensure that your voice is heard in this pressing matter of corporate responsibility and investor protection.
Recently, ImmunityBio reported the findings from its Phase 2 clinical trial for a novel immunotherapy regimen targeting patients suffering from recurrent or progressive glioblastoma, a form of brain cancer. The results highlighted that the primary endpoint concerning median overall survival was pending, which raised significant concerns amongst eager investors. On January 23, 2026, the market reacted to this ambiguous update, resulting in a substantial drop of 12.13% in ImmunityBio's stock price, closing at $6.45 per share.
Compounding these woes, further complications arose on March 24, 2026 when a letter from the U.S. Food and Drug Administration (FDA) became public. The FDA reprimanded ImmunityBio for their continued promotion of Anktiva, a drug used in bladder cancer treatment, accusing the company of using misleading marketing strategies despite prior warnings. This revelation added to investor concerns; the stock plummeted another 21.12%, closing at $7.41 per share.
Pomerantz LLP, renowned for its expertise in corporate and securities class action litigation, has a history spanning over 85 years, championing the rights of investors. Founded by the influential Abraham L. Pomerantz, the firm has strategically tackled various cases of securities fraud, corporate misconduct, and breaches of fiduciary duty. Their record of securing significant damages for victims further emphasizes the commitment to justice and accountability in the corporate realm.
In this latest investigation, the firm aims to determine whether ImmunityBio misled its investors, potentially exposing them to significant financial loss. Through prompt action, the firm seeks to recover losses for affected shareholders and to hold accountable those responsible for any fraudulent practices. Investors who believe they may have suffered losses as a result of these events are warmly invited to connect with the Pomerantz team to discuss their situation and explore available options.
Potential investors and stakeholders are advised to stay updated on the developments surrounding ImmunityBio and the investigation led by Pomerantz Law Firm. Further clarity on the company's operations and communications with investors will likely evolve, potentially influencing market perceptions and stock performance in the coming months. If you wish to engage with the current legal discourse or need expert guidance regarding your legal rights as an investor in ImmunityBio, do not hesitate to contact Pomerantz at [email protected] or call 646-581-9980, extension 7980. Ensure that your voice is heard in this pressing matter of corporate responsibility and investor protection.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.